{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T00:03:32Z","timestamp":1793750612528,"version":"4.6.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jaacap.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.jaac.2017.06.013","type":"journal-article","created":{"date-parts":[[2017,7,8]],"date-time":"2017-07-08T06:31:20Z","timestamp":1499495480000},"page":"784-792","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study"],"prefix":"10.1016","volume":"56","author":[{"given":"Christoph U.","family":"Correll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kohegyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross A.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"McQuade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyllis M.","family":"Salzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaretta","family":"Nyilas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaac.2017.06.013_bib1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/YCO.0b013e32835dcc2a","article-title":"Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach","volume":"26","author":"Schimmelmann","year":"2013","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.jaac.2017.06.013_bib2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/schbul\/sbm109","article-title":"Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia","volume":"34","author":"Kumra","year":"2008","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jaac.2017.06.013_bib3","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/schbul\/19.4.831","article-title":"Schizophrenia with onset in adolescence: an 11-year followup","volume":"19","author":"Krausz","year":"1993","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jaac.2017.06.013_bib4","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/cap.2008.0144","article-title":"A\u00a06-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia","volume":"19","author":"Haas","year":"2009","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2017.06.013_bib5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/CHI.0b013e3181900404","article-title":"Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial","volume":"48","author":"Kryzhanovskaya","year":"2009","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2017.06.013_bib6","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.biopsych.2011.06.021","article-title":"A\u00a0randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents","volume":"70","author":"Singh","year":"2011","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jaac.2017.06.013_bib7","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","article-title":"A\u00a0multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia","volume":"165","author":"Findling","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2017.06.013_bib8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1089\/cap.2011.0092","article-title":"Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial","volume":"22","author":"Findling","year":"2012","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2017.06.013_bib9","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00787-015-0693-5","article-title":"Functional deterioration from the premorbid period to 2 years after the first episode of psychosis in early-onset psychosis","volume":"24","author":"Del Rey-Mejias","year":"2015","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2017.06.013_bib10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.schres.2013.11.018","article-title":"Duration of untreated psychosis predicts functional and clinical outcome in children and adolescents with first-episode psychosis: a 2-year longitudinal study","volume":"152","author":"Fraguas","year":"2014","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jaac.2017.06.013_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2012.02.030","article-title":"Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia","volume":"138","author":"Emsley","year":"2012","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jaac.2017.06.013_bib12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/oxfordjournals.schbul.a033315","article-title":"Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort","volume":"24","author":"Wiersma","year":"1998","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jaac.2017.06.013_bib13","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","article-title":"Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis","volume":"379","author":"Leucht","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaac.2017.06.013_bib14","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jaac.2017.06.013_bib15","series-title":"Full prescribing information","year":"2014"},{"key":"10.1016\/j.jaac.2017.06.013_bib16","series-title":"Full prescribing information","year":"2013"},{"key":"10.1016\/j.jaac.2017.06.013_bib17","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/JCP.0b013e31817dd520","article-title":"Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study","volume":"28","author":"Findling","year":"2008","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.jaac.2017.06.013_bib18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jaac.2017.06.013_bib19","series-title":"Clinical Global Impression Scale (CGI). ECDEU Assessment Manual for Psychopharmacology","first-page":"217","author":"Guy","year":"1976"},{"key":"10.1016\/j.jaac.2017.06.013_bib20","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1176\/ajp.2007.164.7.1035","article-title":"Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants","volume":"164","author":"Posner","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2017.06.013_bib21","series-title":"Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision","year":"2000"},{"key":"10.1016\/j.jaac.2017.06.013_bib22","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2017.06.013_bib23","series-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1016\/j.jaac.2017.06.013_bib24","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/archpsyc.1983.01790100074010","article-title":"Children's Global Assessment Scale (CGAS)","volume":"40","author":"Shaffer","year":"1983","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jaac.2017.06.013_bib25","first-page":"321","article-title":"Enjoyment and satisfaction questionnaire: a new measure","volume":"29","author":"Endicott","year":"1993","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.jaac.2017.06.013_bib26","unstructured":"Posner K, Brent D, Lucas C, et\u00a0al. Columbia Suicide Severity Rating Scale. Available at: http:\/\/cssrs.columbia.edu\/docs\/C-SSRS_1_14_09_Baseline.pdf. Accessed April 19,\u00a02016."},{"key":"10.1016\/j.jaac.2017.06.013_bib27","series-title":"Abnormal Involuntary Movement Scale (AIMS). ECDEU Assessment Manual for Psychopharmacology","first-page":"534","author":"Guy","year":"1976"},{"key":"10.1016\/j.jaac.2017.06.013_bib28","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A\u00a0rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jaac.2017.06.013_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A\u00a0rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1016\/j.jaac.2017.06.013_bib30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/adc.44.235.291","article-title":"Variations in pattern of pubertal changes in girls","volume":"44","author":"Marshall","year":"1969","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jaac.2017.06.013_bib31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/adc.45.239.13","article-title":"Variations in the pattern of pubertal changes in boys","volume":"45","author":"Marshall","year":"1970","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jaac.2017.06.013_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1016\/j.jaac.2017.06.013_bib33","unstructured":"Centers for Disease Control and Prevention, National Center for Health Statistics. Percentile data files with LMS values. US Department of Health and Human Services. Available at: http:\/\/www.cdc.gov\/growthcharts\/percentile_data_files.htm. Accessed May 3,\u00a02016."},{"key":"10.1016\/j.jaac.2017.06.013_bib34","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.4088\/JCP.09m05164yel","article-title":"Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study","volume":"70","author":"Findling","year":"2009","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaac.2017.06.013_bib35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4088\/JCP.11m07104","article-title":"Double-blind, randomized, placebo-controlled long-term maintenance study of aripiprazole in children with bipolar disorder","volume":"73","author":"Findling","year":"2012","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaac.2017.06.013_bib36","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/bdi.12042","article-title":"Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study","volume":"15","author":"Findling","year":"2013","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.jaac.2017.06.013_bib37","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","article-title":"A\u00a0placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder","volume":"48","author":"Marcus","year":"2009","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2017.06.013_bib38","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1542\/peds.2008-3782","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder","volume":"124","author":"Owen","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2017.06.013_bib39","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4088\/JCP.13m08500","article-title":"A\u00a0randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder","volume":"75","author":"Findling","year":"2014","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaac.2017.06.013_bib40","first-page":"45","article-title":"Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials","volume":"43","author":"Ardizzone","year":"2010","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.jaac.2017.06.013_bib41","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.jad.2012.02.030","article-title":"Antipsychotics in pediatric and adolescent patients: a review of comparative safety data","volume":"138","author":"Ben Amor","year":"2012","journal-title":"J\u00a0Affect Disord"},{"key":"10.1016\/j.jaac.2017.06.013_bib42","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1089\/cap.2011.0015","article-title":"Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents","volume":"21","author":"Maayan","year":"2011","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2017.06.013_bib43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/chi.0b013e31815b5cb1","article-title":"Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes","volume":"47","author":"Correll","year":"2008","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2017.06.013_bib44","first-page":"26","article-title":"Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents","volume":"69","author":"Correll","year":"2008","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaac.2017.06.013_bib45","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1399-5618.2010.00798.x","article-title":"Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials","volume":"12","author":"Correll","year":"2010","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.jaac.2017.06.013_bib46","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.eurpsy.2010.09.011","article-title":"Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice","volume":"26","author":"De Hert","year":"2011","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.jaac.2017.06.013_bib47","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jaac.2017.06.013_bib48","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1089\/cap.2015.0097","article-title":"Clinical characteristics and predictors of outcome of schizophrenia-spectrum psychosis in children and adolescents: a systematic review","volume":"26","author":"Stentebjerg-Olesen","year":"2016","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2017.06.013_bib49","doi-asserted-by":"crossref","first-page":"f150","DOI":"10.1136\/bmj.f150","article-title":"Recognition and management of psychosis and schizophrenia in children and young people: summary of NICE guidance","volume":"346","author":"Kendall","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jaac.2017.06.013_bib50","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jaac.2013.02.008","article-title":"Practice parameter for the assessment and treatment of children and adolescents with schizophrenia","volume":"52","author":"McClellan","year":"2013","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"}],"container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856717303192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856717303192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T12:51:35Z","timestamp":1535633495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890856717303192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0890856717303192"],"URL":"https:\/\/doi.org\/10.1016\/j.jaac.2017.06.013","relation":{},"ISSN":["0890-8567"],"issn-type":[{"value":"0890-8567","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Child & Adolescent Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaac.2017.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a92017 American Academy of Child and Adolescent Psychiatry","name":"copyright","label":"Copyright"}]}}